Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Gro...(ation (2006: $5.4 million) which include...)

1 Upfront and milestone payments in 2007 were made to Renovo $75.0 million, Amicus $50.0 million, Alba $25.0 million and Noven $5.9 million.

2 Upfront and milestone payments in 2006 were made to New River $50.0 million, Duramed Pharmaceuticals Inc. ("Duramed") $25.0 million and Warren Pharmaceuticals Inc ("Warren") $5.5 million.

Selling, general and administrative

% of product % of product

2007 sales 2006 sales

_________ _________ _________ _________

SG&A (US GAAP) 1,041.7 48% 835.4 54%

Legal settlements (net) (17.0) -

FAS123R (1) (52.7) (34.4)

_________ _________

Non GAAP SG&A 972.0 45% 801.0 52%

(1) Includes 2005 option catch up charge SG&A expenses increased to $1,041.7 million for the year to December 31, 2007 from $835.4 million in the year to December 31, 2006, an increase of 25% which was substantially less than the product sales increase of 41%.

The increase in SG&A expenses included the impact of the following:

- An increase in the ADHD sales force to promote VYVANSE;

- The cost of the new GI sales force in the US;

- The advertising, promotional and marketing spend to support the launches of VYVANSE, LIALDA and ELAPRASE; and

- A net charge of $17.0 million in respect of legal settlements, being a charge of $27.0 million for settlement of the TKT purported securities fraud class action shareholder suit partially offset by a $10.0 million release of existing legal provisions.

Excluding the net charge for legal settlements and s
'/>"/>